Biology and clinical relevance of human natural killer cells.

Information about subscriptions and ASH membership may be found online at: reserved.

[1]  P. Anderson,et al.  Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. , 1991, Journal of immunology.

[2]  M. Caligiuri,et al.  Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. , 1990, Journal of immunology.

[3]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[4]  M. Alderson,et al.  Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood , 1990, The Journal of experimental medicine.

[5]  T. Grogan,et al.  Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19) , 1990 .

[6]  M. V. D. van den Brink,et al.  The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures , 1990, The Journal of experimental medicine.

[7]  L. Barnett,et al.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.

[8]  J. Ritz,et al.  Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. , 1990, Blood.

[9]  M. Caligiuri,et al.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.

[10]  L. Lanier,et al.  Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo , 1990, The Journal of experimental medicine.

[11]  T. Huizinga,et al.  Neutrophil Fc-gamma receptors: a two-way bridge in the immune system. , 1990, Blood.

[12]  H. Asao,et al.  Interleukin 2 (IL-2)-induced tyrosine phosphorylation of IL-2 receptor p75 [published erratum appears in J Exp Med 1990 Jun 1;171(6):2183] , 1990, The Journal of experimental medicine.

[13]  M. Crumpton,et al.  Activation of human T lymphocytes via the CD2 antigen results in tyrosine phosphorylation of T cell antigen receptor zeta-chains. , 1990, Journal of immunology.

[14]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[15]  W. Chan,et al.  Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study , 1990, Cancer.

[16]  D. Longo,et al.  Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. , 1990, Cancer research.

[17]  T. Grogan,et al.  Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). , 1990, Blood.

[18]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[19]  R. Fisher,et al.  Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. , 1989, Journal of immunology.

[20]  L. Lanier,et al.  Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.

[21]  J. Bourhis,et al.  Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. , 1989, Journal of immunology.

[22]  C. Niemeyer,et al.  Hematopoiesis in vitro coexists with natural killer lymphocytes. , 1989, Blood.

[23]  B. Passlick,et al.  Identification and characterization of a novel monocyte subpopulation in human peripheral blood. , 1989, Blood.

[24]  H. Heslop,et al.  Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. , 1989, Blood.

[25]  K. Okumura,et al.  Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction , 1989, The Journal of experimental medicine.

[26]  J. Thompson,et al.  Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. , 1989, Cancer research.

[27]  D. Harris,et al.  Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor. , 1989, Journal of immunology.

[28]  H. Heslop,et al.  A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. , 1989, British Journal of Cancer.

[29]  M. Favrot,et al.  Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. , 1989, Bone marrow transplantation.

[30]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[31]  P. Henkart,et al.  Induction of target cell DNA release by the cytotoxic T lymphocyte granule protease granzyme A , 1989, The Journal of experimental medicine.

[32]  M. Minden,et al.  T cell receptor delta gene organization and expression in normal and leukemic natural killer cells. , 1989, Journal of immunology.

[33]  G. Pizzolo,et al.  Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission , 1989, Cancer.

[34]  C. Verfaillie,et al.  Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. , 1989, Blood.

[35]  B. Perussia,et al.  Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions , 1989, The Journal of experimental medicine.

[36]  S. Rosenberg,et al.  Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. , 1989, Journal of immunology.

[37]  D. Evans,et al.  Identification of a human natural killer cell target cell antigen with monoclonal antibodies. , 1989, Journal of immunology.

[38]  B. Calabretta,et al.  G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. , 1989, Science.

[39]  D. Zarcone,et al.  Morphologic and functional characterization of human peripheral blood T cells expressing the T cell receptor γ/δ* , 1989 .

[40]  J. Sosman,et al.  Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. , 1989, Cancer research.

[41]  J. Murphy,et al.  Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans , 1989, Infection and immunity.

[42]  S. Roncella,et al.  Production of colony-stimulating activity by human natural killer cells: analysis of the conditions that influence the release and detection of colony-stimulating activity. , 1989, Blood.

[43]  J L Sullivan,et al.  Severe herpesvirus infections in an adolescent without natural killer cells. , 1989, The New England journal of medicine.

[44]  U. Dianzani,et al.  CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine‐activated killer cell precursors , 1989, European journal of immunology.

[45]  R. Testi,et al.  Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule , 1989, The Journal of experimental medicine.

[46]  I. Weissman,et al.  IL-2 induces expression of serine protease enzymes and genes in natural killer and nonspecific T killer cells. , 1989, Journal of immunology.

[47]  S. Rosenberg,et al.  IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. , 1989, Journal of immunology.

[48]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[49]  R. Fisher,et al.  A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  H. Friedman,et al.  Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: role of LFA-1. , 1989, Cellular immunology.

[51]  H. Heslop,et al.  Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.

[52]  K. Sullivan,et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.

[53]  J. Young,et al.  Mechanisms of lymphocyte‐mediated lysis , 1989, Journal of cellular biochemistry.

[54]  M. Tigges,et al.  Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway. , 1989, Science.

[55]  R. Fisher,et al.  A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  E. Lotzová,et al.  Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias. , 1989, Experimental hematology.

[57]  P. Lipsky,et al.  Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2. , 1989, Journal of biological response modifiers.

[58]  J. Unkeless.  Function and heterogeneity of human Fc receptors for immunoglobulin G. , 1989, The Journal of clinical investigation.

[59]  G. Trinchieri,et al.  Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes , 1989, The Journal of experimental medicine.

[60]  G. Trinchieri,et al.  Production of hematopoietic colony-stimulating factors by human natural killer cells , 1989, The Journal of experimental medicine.

[61]  R. O. Kelley,et al.  Antibacterial activity of human natural killer cells , 1989, The Journal of experimental medicine.

[62]  T. Whiteside,et al.  Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. , 1988, Blood.

[63]  R. Hoover,et al.  Gene Expression Associated with Natural Killer Function , 1989 .

[64]  B. Fox,et al.  Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. , 1989, Cancer immunology, immunotherapy : CII.

[65]  S. Pirruccello,et al.  Acute lymphoblastic leukemia of NK-cell lineage: responses to IL-2. , 1989, Leukemia research.

[66]  C. Riccardi,et al.  Effect of various cytokines and growth factors on the interleukin-2-dependent in vitro differentiation of natural killer cells from bone marrow. , 1989, Natural immunity and cell growth regulation.

[67]  L. Owen-Schaub,et al.  Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. , 1989, Cancer research.

[68]  S. Jones,et al.  Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Lobo,et al.  Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells. , 1989, The Journal of clinical investigation.

[70]  J. Mier,et al.  IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. , 1988, Journal of immunology.

[71]  R. Klausner,et al.  The T cell antigen receptor zeta chain is tyrosine phosphorylated upon activation. , 1988, The Journal of biological chemistry.

[72]  G. Gersuk,et al.  Inhibition of human natural killer cell activity by platelet-derived growth factor. II. Membrane binding studies, effects of recombinant IFN-alpha and IL-2, and lack of effect on T cell and antibody-dependent cellular cytotoxicity. , 1988, Journal of immunology.

[73]  G. Powis,et al.  Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. , 1988, Journal of immunology.

[74]  R. Fisher,et al.  Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. , 1988, Cancer research.

[75]  R. Hoover,et al.  Changes in gene expression associated with IFN-beta and IL-2-induced augmentation of human natural killer cell function. , 1988, Journal of immunology.

[76]  A. Montag,et al.  Immunophenotype of small cell lung carcinoma: Expression of NKH‐1 and transferrin receptor and absence of most myeloid antigens , 1988, Cancer.

[77]  D. Littman,et al.  A second subunit of CD8 is expressed in human T cells. , 1988, The EMBO journal.

[78]  J. Bonifacino,et al.  T cell CD3-zeta eta heterodimer expression and coupling to phosphoinositide hydrolysis. , 1988, Science.

[79]  D. Evans,et al.  Characterization by monoclonal antibodies of a target cell antigen complex recognized by nonspecific cytotoxic cells. , 1988, Journal of immunology.

[80]  Anthony J. Sinskey,et al.  Protein kinase C is required for responses to T cell receptor ligands but not to interleukin-2 in T cells , 1988, Cell.

[81]  K. Oshimi.  Granular lymphocyte proliferative disorders: report of 12 cases and review of the literature. , 1988, Leukemia.

[82]  L. Lanier,et al.  The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. , 1988, Journal of immunology.

[83]  C. Payá,et al.  Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity. , 1988, Journal of immunology.

[84]  J. Blay,et al.  Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Gahmberg,et al.  CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. , 1988, Journal of immunology.

[86]  A. Kuramoto,et al.  Aggressive natural killer cell leukemia/lymphoma with N901-positive surface phenotype: evidence for the existence of a third lineage in lymphoid cells. , 1988, Acta haematologica.

[87]  H. Ploegh,et al.  Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression. Direct demonstration using beta 2-microglobulin-transfected Daudi cells. , 1988, Journal of immunology.

[88]  T. Whiteside,et al.  A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. , 1988, Cancer research.

[89]  S. Sone,et al.  Differential Effects of Recombinant Interferons α, β, and γ on Induction of Human Lymphokine (IL–2)–Activated Killer Activity , 1988 .

[90]  M. Caligiuri,et al.  Induction of natural killer effectors from human thymus with recombinant IL-2. , 1988, Journal of immunology.

[91]  P. Greenberg,et al.  IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. , 1988, Journal of immunology.

[92]  R. Bechhofer,et al.  Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. , 1988, Cancer research.

[93]  J. Sunshine,et al.  The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. , 1988, Science.

[94]  R. Fisher,et al.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. , 1988, Annals of internal medicine.

[95]  R. Bechhofer,et al.  Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. , 1988, Journal of the National Cancer Institute.

[96]  W. Boswell,et al.  Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  R. Fisher,et al.  In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. , 1988, Journal of immunology.

[98]  J. Ritz,et al.  T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules. , 1988, Journal of immunology.

[99]  G. Trinchieri,et al.  Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells , 1988, The Journal of experimental medicine.

[100]  A. Maghazachi,et al.  Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells , 1988, The Journal of experimental medicine.

[101]  O. Carpén,et al.  Directed exocytosis in the NK-cell-mediated cytotoxicity. A review. , 1988, Natural immunity and cell growth regulation.

[102]  A. Fischer,et al.  Leukocyte adhesion deficiency: molecular basis and functional consequences. , 1988, Immunodeficiency reviews.

[103]  W. Greene,et al.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. , 1988, The Journal of clinical investigation.

[104]  R. Foà,et al.  In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. , 1988, Leukemia.

[105]  T. Whiteside,et al.  Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. , 1988, Blood.

[106]  L. Lanier,et al.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[108]  C. Rosse,et al.  The primary role of murine bone marrow in the production of natural killer cells. A cytokinetic study. , 1987, Journal of immunology.

[109]  Kendall A. Smith,et al.  The interleukin 2 receptor. Functional consequences of its bimolecular structure , 1987, The Journal of experimental medicine.

[110]  G. Starkebaum,et al.  Large Granular Lymphocyte Leukemia: REPORT OF 38 CASES AND REVIEW OF THE LITERATURE , 1987, Medicine.

[111]  L. Lanier,et al.  Acquisition of non-MHC restricted cytotoxic function by IL 2 activated thymocytes with an "immature" antigenic phenotype. , 1987, Journal of immunology.

[112]  W. Chan,et al.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[113]  B. Autran,et al.  rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2. , 1987, Journal of immunology.

[114]  T. Klein,et al.  Cytolytic activity of human peripheral blood leukocytes against Legionella pneumophila-infected monocytes: characterization of the effector cell and augmentation by interleukin 2. , 1987, Journal of immunology.

[115]  G. Edelman,et al.  Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. , 1987, Science.

[116]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[117]  L. Lanier,et al.  Expression of Leu-19 (NKH-1) antigen on IL 2-dependent cytotoxic and non-cytotoxic T cell lines. , 1987, Journal of immunology.

[118]  P. Cresswell,et al.  NK susceptibility varies inversely with target cell class I HLA antigen expression. , 1987, Journal of immunology.

[119]  B. Bonavida,et al.  Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor. , 1987, Journal of immunology.

[120]  J. Seidman,et al.  A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes , 1987, Nature.

[121]  J. D. Young,et al.  Cellular and humoral mechanisms of cytotoxicity: structural and functional analogies. , 1987, Advances in immunology.

[122]  M. Bennett,et al.  Biology and genetics of hybrid resistance. , 1987, Advances in immunology.

[123]  E. Lotzová,et al.  Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. , 1987, Leukemia research.

[124]  F. Balkwill,et al.  DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon‐γ , 1987, European journal of immunology.

[125]  E. Reinherz,et al.  Enhancement of natural killer function through activation of the T11 E rosette receptor. , 1987, The Journal of clinical investigation.

[126]  J. Ritz,et al.  In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. , 1987, Blood.

[127]  K C Zoon,et al.  Interferons and their actions. , 1987, Annual review of biochemistry.

[128]  G. Trinchieri,et al.  Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. , 1986, Journal of immunology.

[129]  L. Lanier,et al.  Natural killer cells: definition of a cell type rather than a function. , 1986, Journal of immunology.

[130]  W. Chan,et al.  Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes. , 1986, Blood.

[131]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[132]  A. Harel-Bellan,et al.  Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[133]  J. Ritz,et al.  A subset of natural killer cells in peripheral blood displays a mature T cell phenotype , 1986, The Journal of experimental medicine.

[134]  L. Lanier,et al.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. , 1986, Journal of immunology.

[135]  B. Zwilling,et al.  Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction. , 1986, Cancer research.

[136]  M. Brunda,et al.  Interaction of recombinant interferons with recombinant interleukin‐2: Differential effects on natural killer cell activity and interleukin‐2‐activated killer cells , 1986, International journal of cancer.

[137]  G. Bosma,et al.  Transplantable progenitors of natural killer cells are distinct from those of T and B lymphocytes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[138]  B. Pope,et al.  Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line , 1986 .

[139]  T. Sayers,et al.  Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation. , 1986, Journal of immunology.

[140]  C. Rooney,et al.  Natural killer cell activity following T‐cell depleted allogeneic bone marrow transplantation , 1986, British journal of haematology.

[141]  J. Tite,et al.  DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[142]  K. Anderson,et al.  Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. , 1986, Blood.

[143]  J Stein-Streilein,et al.  In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. , 1986, Journal of immunology.

[144]  N. Federspiel,et al.  Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor beta chain genes , 1986, The Journal of experimental medicine.

[145]  Welsh Rm.  Regulation of virus infections by natural killer cells. A review. , 1986 .

[146]  L. Lanier,et al.  A Map of the Cell Surface Antigens Expressed on Resting and Activated Human Natural Killer Cells , 1986 .

[147]  V. Tsai,et al.  Acute toxoplasma infection of mice induces spleen NK cells that are cytotoxic for T. gondii in vitro. , 1986, Journal of immunology.

[148]  G. Gersuk,et al.  Inhibition of human natural killer cell activity by platelet-derived growth factor. , 1986, Natural immunity and cell growth regulation.

[149]  Y. Takei,et al.  Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. , 1986, Blood.

[150]  C. Bordignon,et al.  Hematopoietic histoincompatibility reactions by NK cells in vitro: model for genetic resistance to marrow grafts. , 1985, Science.

[151]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[152]  G. Dennert,et al.  Cytotoxic granules from killer cells: specificity of granules and insertion of channels of defined size into target membranes. , 1985, Journal of immunology.

[153]  T. Kipps,et al.  Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen) , 1985, The Journal of experimental medicine.

[154]  David A. Amato,et al.  Specific release of proteoglycans from human natural killer cells during target lysis , 1985, Nature.

[155]  G. Trinchieri,et al.  Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon , 1985, The Journal of experimental medicine.

[156]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[157]  J. Ritz,et al.  Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. , 1985, Journal of immunology.

[158]  J. Varani,et al.  Expression of a laminin-like substance on the surface of murine natural killer (NK) lymphocytes and its role in NK recognition of tumor target cells. , 1985, Journal of immunology.

[159]  E. Reinherz,et al.  Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. , 1985, Science.

[160]  M. Bennett,et al.  Origin and differentiation of natural killer cells. I. Characteristics of a transplantable NK cell precursor. , 1985, Journal of immunology.

[161]  S. Orkin,et al.  Phenotype of recovering lymphoid cell populations after marrow transplantation , 1985, The Journal of experimental medicine.

[162]  Craig W. Reynolds,et al.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. , 1985, Journal of immunology.

[163]  J. Sissons,et al.  Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells. , 1985, Journal of immunology.

[164]  J. Ritz,et al.  Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. , 1985, The Journal of clinical investigation.

[165]  L. Lanier,et al.  Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. , 1985, Journal of immunology.

[166]  R. Welsh,et al.  Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo , 1985, The Journal of experimental medicine.

[167]  J. Taylor‐Papadimitriou.  Interferons, their impact in biology and medicine , 1985 .

[168]  Craig W. Reynolds,et al.  T gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristics , 1984 .

[169]  A. Komiyama,et al.  Childhood acute lymphoblastic leukemia with natural killer activity. Clinical and cellular features of three cases , 1984, Cancer.

[170]  G. Trinchieri,et al.  Phorbol esters enhance spontaneous cytotoxicity of human lymphocytes, abrogate Fc receptor expression, and inhibit antibody-dependent lymphocyte-mediated cytotoxicity. , 1984, Journal of immunology.

[171]  G. Trinchieri,et al.  Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.

[172]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.

[173]  H. Shepard,et al.  Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. , 1984, Journal of immunology.

[174]  G. Trinchieri,et al.  The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. , 1984, Journal of immunology.

[175]  D. Niederwieser,et al.  Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. , 1984, Blood.

[176]  B. V. van Krimpen,et al.  Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells. , 1984, Journal of immunology.

[177]  P. Allavena,et al.  Characteristics of human NK clones: target specificity and phenotype. , 1984, Journal of immunology.

[178]  G. Trinchieri,et al.  Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells. , 1984, Journal of immunology.

[179]  D. Strayer,et al.  Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. , 1984, Cancer Research.

[180]  G F Babcock,et al.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. , 1983, Journal of immunology.

[181]  J. Roth,et al.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells , 1983, The Journal of experimental medicine.

[182]  B. Woda,et al.  Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. , 1983, Journal of immunology.

[183]  G. Luquet,et al.  Spontaneous and induced cytotoxicity of axial organ cells from Asterias rubens (Asterid--echinoderm). , 1983, Immunology letters.

[184]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[185]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells , 1983, The Journal of experimental medicine.

[186]  E. Reinherz,et al.  Phenotypic and functional heterogeneity of human cloned natural killer cell lines , 1983, Nature.

[187]  G. Dennert,et al.  Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo , 1982, Nature.

[188]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[189]  J. Ortaldo,et al.  Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. , 1981, Journal of immunology.

[190]  R. Burton,et al.  Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. , 1981, Journal of immunology.

[191]  N. Ghossein,et al.  Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. , 1981, Journal of immunology.

[192]  J. Ortaldo,et al.  Natural killer cells: their roles in defenses against disease. , 1981, Science.

[193]  C. Balch,et al.  A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). , 1981, Journal of immunology.

[194]  J. Decker,et al.  Spontaneous cytotoxicity mediated by invertebrate mononuclear cells toward normal and malignant vertebrate targets: inhibition by defined mono- and disaccharides. , 1981, Cellular immunology.

[195]  J. Ortaldo,et al.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells , 1981, The Journal of experimental medicine.

[196]  J. Djeu,et al.  Metabolic requirements for the in vitro augmentation of mouse natural killer activity by interferon. , 1981, Cellular immunology.

[197]  D. Purtilo,et al.  Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. , 1980, Science.

[198]  J. Mier,et al.  Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[199]  E. Saksela,et al.  Isolation of human NK cells by density gradient centrifugation. , 1980, Journal of immunological methods.

[200]  G. Dennert.  Cloned lines of natural killer cells , 1980, Nature.

[201]  J. Talmadge,et al.  Role of NK cells in tumour growth and metastasis in beige mice , 1980, Nature.

[202]  J. Roder,et al.  A new immunodeficiency disorder in humans involving NK cells , 1980, Nature.

[203]  P. Hersey,et al.  Low natural-killer-cell activity in familial melanoma patients and their relatives. , 1979, British Journal of Cancer.

[204]  O. Haller,et al.  Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo , 1977, Nature.

[205]  O. Haller,et al.  Generation of natural killer cells: an autonomous function of the bone marrow , 1977, The Journal of experimental medicine.

[206]  M. Bortin.  GRAFT-VERSUS-LEUKEMIA , 1974 .

[207]  P. Levine,et al.  Lymphocyte cytotoxicity reactions to leukemia‐associated antigens in identical twins , 1972, International journal of cancer.

[208]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.